The Evaluation of the Eighth Edition of the AJCC/UICC Staging System for Intrahepatic Cholangiocarcinoma: a Proposal of a Modified New Staging System
- 54 Downloads
The objective was to clarify the prognostic impact of the 8th edition of American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) of intrahepatic cholangiocarcinoma (ICC).
A total of 103 ICC patients who underwent hepatectomy between 2002 and 2016 were enrolled. The survival impact of AJCC/UICC 8th edition was examined.
The 5-year disease-specific survival (DSS) rate was 75.9% in T1a (n = 23), 88.9% in T1b (n = 10), 14.9% in T2 (n = 24), 52.5% in T3 (n = 11), and 15.2% in T4 (n = 35). The DSS was comparable among T2, T3, and T4 (T2 vs. T3; p = 0.345, T3 vs. T4; 0.295). A multivariate analysis identified multiple tumors (hazard ratio [HR] 2.821), periductal infiltrating (HR 2.439), perforation of the visceral peritoneum (HR 1.850), and vascular invasion (HR 1.872) as independent prognostic factors that were associated with the DSS. The optimum tumor size with the greatest difference in the DSS was 2 cm (p = 0.014). The new T classification was developed as follows: T1, size ≤ 2 cm without other factors; T2, size > 2 cm without other factors; T3, vascular invasion or perforation of the visceral peritoneum; and T4, multiple tumors or periductal infiltrating. The 5-year DSS was 100% in T1 (n = 7), 76.6% in T2 (n = 28), 45.1% in T3 (n = 28), and 3.4% in T4 (n = 40). There were differences in the DSS between T2 and T3 (p = 0.035) and between T3 and T4 (p = 0.003).
T2, T3, and T4 of AJCC/UICC overlapped with regard to the DSS. The new staging can classify ICC patients with sufficient prognostic differences.
KeywordsIntrahepatic cholangiocarcinoma AJCC/UICC 8th edition Multiple tumor Vascular invasion Lymph node metastasis
American Joint Committee on Cancer
International Union Against Cancer
Liver Cancer Study Group of Japan
Design of work: Y Yamamoto, T Sugiura, and K Uesaka
Acquisition, analysis, and interpretation of data: Y Yamamoto, T Sugiura, Y Okamura, T Ito, R Ashida, K Ohgi, and Y Nakanuma
Drafting and revising: Y Yamamoto, T Sugiura, Y Okamura, T Ito, R Ashida, K Ohgi, and K Uesaka
Final approval: Y Yamamoto, T Sugiura, Y Okamura, T Ito, R Ashida, K Ohgi, and K Uesaka
Agreement to be accountable for all aspects of the work: Y Yamamoto, T Sugiura, Y Okamura, T Ito, R Ashida, K Ohgi, Y Nakanuma, and K Uesaka
Compliance with Ethical Standards
The Institutional Review Board approved this study.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 7.Yamamoto Y, Sugiura T, Todaka A, Okamura Y, Ito T, Ashida R et al. Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value. World J Surg. 2018. 42(10):3331–40. doi: https://doi.org/10.1007/s00268-018-4605-y.CrossRefGoogle Scholar
- 12.Sobin LH. TNM Classification of Malignant Tumours seventh edition. 2009.Google Scholar
- 13.Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer. 2011;117(10):2170–7. doi: https://doi.org/10.1002/cncr.25712.CrossRefGoogle Scholar
- 14.Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M et al. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer. 2016;122(1):61–70. doi: https://doi.org/10.1002/cncr.29686.CrossRefGoogle Scholar
- 16.Uenishi T, Ariizumi S, Aoki T, Ebata T, Ohtsuka M, Tanaka E et al. Proposal of a new staging system for mass-forming intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2014;21(7):499–508. doi: https://doi.org/10.1002/jhbp.92.CrossRefGoogle Scholar
- 17.Brierley JD. TNM Classification of Malignant Tumours eight edition. 2017.Google Scholar
- 22.Spolverato G, Bagante F, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L et al. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. J Surg Oncol. 2017;115(6):696–703. doi: https://doi.org/10.1002/jso.24569.CrossRefGoogle Scholar
- 23.Sasaki K, Margonis GA, Andreatos N, Bagante F, Weiss M, Barbon C et al. Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. J Am Coll Surg. 2018;226(4):393–403. doi: https://doi.org/10.1016/j.jamcollsurg.2017.12.011 CrossRefGoogle Scholar
- 28.Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg. 2007;31(10):2016–22.CrossRefGoogle Scholar